The Evolving Landscape of Cancer Vaccines

We often think of vaccines as tools that help prevent infectious diseases before they occur. Therapeutic cancer vaccines serve a different purpose. They are used after a cancer diagnosis to treat active cancer or to help the immune system recognize and eliminate residual cancer cells that could contribute to recurrence. They work by teaching the immune system to identify and attack cancer-associated features on cells that arose from the body’s own tissues.

Cancer vaccines are an active area of research, with encouraging results emerging in selected patients and clinical settings. However, they are not yet an established treatment for most cancers. Advances in vaccine design, biomarker selection, and combination strategies have renewed interest in their role for treating cancer and reducing the risk of recurrence.

At Private Health Management (PHM), we follow the latest science across cancer care, including emerging approaches such as cancer vaccines. Here, we review how therapeutic cancer vaccines work, what recent research is showing, and the questions that remain about their potential role in patient care.

Why Cancer Vaccines Are So Challenging to Develop
Cancer vaccines are difficult to develop because cancer cells may carry mutations and abnormal proteins, but they still resemble normal tissue. In addition, tumors can suppress nearby immune cells, may change over time, and often differ substantially from one patient to another. Together, these challenges make it difficult to design a vaccine that helps the immune system recognize the cancer without harming healthy cells and that continues to work as the tumor changes.

Researchers have spent more than 30 years trying to overcome these challenges using a variety of strategies that aim to help the immune system recognize and attack cancer. Early strategies used whole cancer cells, material made by breaking down tumor tissue (tumor lysates), shared cancer proteins, or immune cells exposed to tumor material.

Current approaches may deliver short pieces of protein called peptides, genetic instructions such as messenger RNA (mRNA), or broader collections of RNA and proteins taken from the tumor. Some vaccines target abnormalities shared by groups of patients while others are built specifically around an individual patient’s cancer.

From Tumor Sequencing to a Personalized Vaccine
One of the most active areas in this field is the development of personalized neoantigen vaccines. Neoantigens are tumor-specific targets created by mutations within an individual’s cancer. Because these targets are often unique to each tumor, a vaccine can be designed to direct the immune system against the molecular features of one patient’s cancer.

Building a personalized neoantigen vaccine is an intensive process. It often involves:

• Comparing tumor DNA with normal DNA, often using whole-exome sequencing, which examines thousands of genes at once to look for changes;
• Analyzing tumor RNA to identify active mutations or changes
• Selecting the abnormal features or targets that are most likely to be recognized by the immune system.

One of the biggest challenges in developing a personalized cancer vaccine is deciding which tumor changes to pursue. Not every mutation becomes a useful target, and not every selected target produces the immune response needed to attack cancer. Researchers look for changes that are most likely to activate T cells because they are among the immune cells responsible for recognizing and killing abnormal cells. Targets differ among vaccines, and prediction systems can rank the same mutations differently. As a result, two platforms could build different vaccines from the same tumor. The success of a personalized vaccine may therefore depend as much on selecting the right targets as on how those targets are delivered.

Choosing the Vaccine Platform
Personalized neoantigen vaccines can deliver information to the immune system in different ways. Some use a collection of peptides along with an immune-stimulating substance (adjuvant), while others use mRNA which gives cells temporary instructions to make those same abnormal proteins.

Much of the field’s recent momentum has shifted toward RNA-based vaccines. They can include many targets in one vaccine, have performed well in early studies, and are advancing rapidly in clinical development

However, enthusiasm for RNA may be moving faster than the evidence in patients. The relative clinical advantages of RNA and peptide vaccines remain uncertain, and the optimal approach may differ across patients and clinical settings. Moving forward, we should recognize the promise and potential of RNA vaccines while not losing sight of the continued value of peptide-based approaches.

The best approach may depend on the cancer, the targets selected, the prediction system, the vaccine formulation and route of administration, and the patient’s underlying immune biology.

What Recent Studies are Showing
Recent studies have renewed interest in cancer vaccines by reporting not only immune responses but also encouraging signs that some patients may benefit. The findings are still early, and the studies differ in size and design, but several results are worth watching.

Why Some Patients Develop Long-Term Responses
A recurring pattern across cancer-vaccine studies is that the benefits most often occur in a subset of patients. Some patients develop strong and persistent vaccine-specific immune responses. Others develop weak responses or none at all. In several studies, the stronger immune responders have also experienced longer periods without cancer recurrence or unexpectedly long survival.

Researchers are still trying to understand whether the vaccine helps create these long-term responders or whether certain patients are more likely to benefit because of their underlying immune biology. Larger randomized studies and better biomarkers are needed to help identify which patients are most likely to respond.

An Army at the Gates
A cancer vaccine may train the immune system to generate an “army” of T cells that can recognize cancer. But recognition alone is not enough. These cells must also reach and enter the tumor, remain active, and resist signals from cancer that can weaken or shut down the immune response. This is why the timing of vaccination and the treatments given with it may be important.

Vaccination may have a better chance of working when the amount of cancer is relatively small. Several encouraging studies have treated patients after surgery, when visible disease has been removed but microscopic cancer cells may remain. In this setting, the immune system has fewer cancer cells to confront and may face less of the immune-suppressing environment created by a larger tumor.

Combination treatment may also help vaccine-activated T cells overcome the remaining barriers. Immune checkpoint inhibitors can release some of the “brakes” on immune cells. Chemotherapy, radiation, targeted therapy, and other immune-modulating treatments may also alter the tumor environment in ways that help T cells enter the tumor, remain active, and respond more effectively.

The Practical Challenges of Cancer Vaccines
At PHM, cancer vaccines are among the most intriguing therapies we help clients explore. Among clients who have pursued them, we have observed a range of clinical courses. Some have experienced outcomes that appeared more favorable or durable than anticipated, while others have had slower disease progression without a dramatic response. Some have had no obvious benefit. Because cancer vaccines are generally used as part of a broader treatment plan, these individual experiences cannot establish how much, if at all, the vaccine contributed to an outcome. They nevertheless inform our interest in the field while reinforcing the limits of what any one case can show.

There are also several practical challenges to consider.

• Difficulty measuring impact: Cancer vaccines are usually given as part of a broader treatment plan, so it can be difficult to know how much the vaccine contributed to an individual patient’s outcome.
• Uncertain outcomes: Cancer vaccines do not help every patient, and there is currently no reliable way to predict who will benefit.
• Potential side effects: In the studies reviewed here, vaccine-related side effects have generally been manageable, but these treatments are not risk-free. Other therapies given alongside a vaccine, including immune checkpoint inhibitors, may add further risks.
• Limited access: Cancer vaccines are not widely available. Patients may need to explore clinical trials, single-patient expanded access, or selected programs outside the United States. At PHM, we have helped clients evaluate and pursue these pathways when appropriate.

Pursuing a cancer vaccine is also a complex process that may require confirming that enough tumor tissue is available, completing molecular testing, selecting targets, coordinating manufacturing and regulatory requirements, and planning travel and treatment. The laboratories, vaccine manufacturer, physicians, and patient may all be in different institutions or countries. Patients and families who pursue these paths often accept significant uncertainty, time, travel, and logistical demands without any guarantee of benefit. Their commitment should be matched by careful scientific review, realistic expectations, and close coordination among everyone involved.

Looking Ahead
The science has demonstrated that cancer vaccines can produce an immune response. The more important question is whether that response can reach the cancer, remain active, and lead to meaningful clinical benefit.

Several factors may shape whether a vaccine succeeds:

• Choosing the right targets: The vaccine must focus on tumor changes that the immune system can recognize and attack.
• Using the right approach: Success is unlikely to come down simply to RNA versus peptide. Different cancers and patients may respond better to different vaccine designs.
• Treating at the right time: Vaccines may be more effective when there is less cancer present, such as after surgery.
• Combining treatments effectively: Other therapies may help vaccine-generated immune cells reach the tumor and overcome its defenses.
• Identifying likely responders: Researchers still need to understand why some patients develop strong, durable responses while others do not.

Another developing frontier is the use of vaccines to prevent cancer in people at unusually high risk of developing the disease by training the immune system to recognize abnormal changes before a tumor develops.

Cancer vaccines are not yet a proven solution for most patients. They are also no longer merely a theoretical idea. Encouraging signals are appearing across different cancers, particularly among patients who develop lasting immune responses, which supports continued attention and serious study.

At PHM, our experts help clients understand whether a cancer vaccine may be worth exploring, identify possible routes to access, and navigate the scientific, logistical, and clinical coordination these treatments can require.